Clinical trials
Genital Neoplasms, Female trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
75 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 3 |
| 2005 | 2 |
| 2006 | 4 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 10 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 6 |
| 2020 | 4 |
| 2021 | 6 |
| 2022 | 4 |
| 2023 | 4 |
| 2024 | 4 |
| 2025 | 6 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 34 |
| Unknown status | 12 |
| Recruiting | 11 |
| Active, not recruiting | 8 |
| Terminated | 5 |
| Withdrawn | 2 |
| Not yet recruiting | 2 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Eli Lilly and Company | 4 |
| KU Leuven | 2 |
| M.D. Anderson Cancer Center | 2 |
| Xiaoxiang Chen | 2 |
| AA Secord | 1 |
| Advaxis, Inc. | 1 |
| Alterome Therapeutics, Inc. | 1 |
| Amgen | 1 |
| Arsenal Biosciences, Inc. | 1 |
| Atavistik Bio, Inc | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Genital Neoplasms, Female | 75 |
| Ovarian Neoplasms | 37 |
| Endometrial Neoplasms | 23 |
| Uterine Cervical Neoplasms | 22 |
| Neoplasms | 20 |
| Urogenital Neoplasms | 16 |
| Uterine Neoplasms | 16 |
| Fallopian Tube Neoplasms | 12 |
| Genital Diseases, Female | 12 |
| Neoplasms by Site | 12 |
Trials
Showing 1 to 25 of 75. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.